We are live on ! Find out more
HS

HighVista Strategies Portfolio holdings

AUM $362M
1-Year Est. Return 230.96%
This Fund
S&P 500
This Quarter Est. Return
+3.78%
1 Year Est. Return
+230.96%
3 Year Est. Return
+518.4%
5 Year Est. Return
+644.94%
10 Year Est. Return
+2,223.31%
AUM
$274M
AUM Growth
-$6.67M
Cap. Flow
-$848K
Cap. Flow %
-0.31%
Top 10 Hldgs %
29.37%
Holding
164
New
33
Increased
27
Reduced
41
Closed
27

Top Buys

Rank Stock Value
1
CTLT
CATALENT, INC.
CTLT
+$4.22M
2
ETRN
Equitrans Midstream Corporation Common Stock
ETRN
+$4.16M
3
HCP
HashiCorp, Inc. Class A Common Stock
HCP
+$4.05M
4
CRM icon
Salesforce
CRM
+$2.28M
5
TEVA icon
Teva Pharmaceuticals
TEVA
+$2.1M

Top Sells

Rank Stock Value
1
SP
SP Plus Corporation
SP
+$4.12M
2
OFIX icon
Orthofix Medical
OFIX
+$2.44M
3
IDYA icon
IDEAYA Biosciences
IDYA
+$2.31M
4
IMCR icon
Immunocore
IMCR
+$2.26M
5
NUVL
Nuvalent
NUVL
+$2.23M

Sector Composition

Rank Sector Weight
1 Healthcare 43.71%
2 Technology 17%
3 Consumer Discretionary 6.54%
4 Energy 4.11%
5 Consumer Staples 3.64%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TERN
101
DELISTED
Terns Pharmaceuticals
TERN
$1.01M 0.37%
148,200
– –
JANX icon
102
Janux Therapeutics
JANX
$1B
$977K 0.36%
+23,332
New +$1.1M
IMTX icon
103
Immatics
IMTX
$1.33B
$904K 0.33%
+77,821
New +$877K
GERN icon
104
Geron
GERN
$949M
$762K 0.28%
179,799
-60,435
-25% -$236K
CRH icon
105
CRH
CRH
$66.9B
$757K 0.28%
10,100
-1,100
-10% -$87.8K
PTGX icon
106
Protagonist Therapeutics
PTGX
$9.71B
$736K 0.27%
21,229
– –
BILI icon
107
Bilibili
BILI
$7.95B
$723K 0.26%
46,857
-41,000
-47% -$571K
MDGL icon
108
Madrigal Pharmaceuticals
MDGL
$11.9B
$710K 0.26%
2,534
– –
MIRM icon
109
Mirum Pharmaceuticals
MIRM
$6.02B
$691K 0.25%
20,208
– –
ABVX
110
Abivax
ABVX
$11.1B
$655K 0.24%
49,509
-8,253
-14% -$118K
HTHT icon
111
Huazhu Hotels Group
HTHT
$13.2B
$634K 0.23%
19,029
-6,900
-27% -$260K
ALNY icon
112
Alnylam Pharmaceuticals
ALNY
$29B
$632K 0.23%
+2,602
New +$411K
ASND icon
113
Ascendis Pharma A/S
ASND
$16.8B
$617K 0.23%
4,527
– –
RYTM icon
114
Rhythm Pharmaceuticals
RYTM
$7.95B
$590K 0.22%
14,362
– –
TCOM icon
115
Trip.com Group
TCOM
$29.7B
$553K 0.2%
11,756
-873
-7% -$44.4K
JD icon
116
JD.com
JD
$45.2B
$496K 0.18%
19,183
-43,282
-69% -$1.27M
VRNA
117
DELISTED
Verona Pharma
VRNA
$469K 0.17%
32,449
– –
UTHR icon
118
United Therapeutics
UTHR
$22.7B
$449K 0.16%
+1,409
New +$373K
OCUL icon
119
Ocular Therapeutix
OCUL
$2.03B
$423K 0.15%
+61,859
New +$382K
ACAD icon
120
Acadia Pharmaceuticals
ACAD
$5.06B
$421K 0.15%
+25,878
New +$418K
NTRA icon
121
Natera
NTRA
$45.9B
$386K 0.14%
+3,568
New +$362K
KALV
122
DELISTED
KalVista Pharmaceuticals
KALV
$375K 0.14%
31,873
– –
SRPT icon
123
Sarepta Therapeutics
SRPT
$1.81B
$374K 0.14%
+2,364
New +$304K
BIDU icon
124
Baidu
BIDU
$37.1B
$362K 0.13%
4,186
-1,300
-24% -$131K
TSVT
125
DELISTED
2seventy bio
TSVT
$360K 0.13%
93,500
– –
3 4
5
6 7

Similar funds

SIAG
Safeguard Investment Advisory Group Corona, California $362M AUM 20.96% 1-Year Est. Return
WI
WBI Investments Red Bank, New Jersey $362M AUM 23.75% 1-Year Est. Return
MS
Millington Securities Red Bank, New Jersey $362M AUM
WTFG
Wood Tarver Financial Group Boise, Idaho $362M AUM 14.75% 1-Year Est. Return
VIA
Virtus Investment Advisers Hartford, Connecticut $363M AUM 34.89% 1-Year Est. Return
A6
Anchor @ 65 Singapore $362M AUM 20.02% 1-Year Est. Return
PI
Pennant Investors Summit, New Jersey $361M AUM 134.26% 1-Year Est. Return
ACM
Anfield Capital Management Irvine, California $363M AUM 24.08% 1-Year Est. Return

HighVista Strategies's Q2 2024 Portfolio in Review

As of Q2 2024, HighVista Strategies held 164 positions worth $274M, down 2.4% from $280M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

HighVista Strategies's Q2 2024 filing shows 33 new, 27 increased, 41 reduced and 27 closed positions. Its largest new stake was CATALENT, INC.: 75,600 shares worth $4.25M. The largest sale was SP Plus Corporation, an estimated $4.12M.

By sector, the portfolio is most concentrated in Healthcare at 44% of assets, down from 45% a quarter earlier, followed by Technology and Consumer Discretionary.

  • HighVista Strategies's largest Q2 2024 buy was CATALENT, INC.: 75,600 shares worth $4.25M.
  • HighVista Strategies added most to Salesforce in Q2 2024, an estimated $2.28M increase.
  • HighVista Strategies's biggest Q2 2024 reduction was IDEAYA Biosciences, cutting an estimated $2.31M.
  • HighVista Strategies fully exited SP Plus Corporation in Q2 2024, selling an estimated $4.12M.
  • HighVista Strategies's ten largest holdings make up 29% of its $274M portfolio in Q2 2024.
  • HighVista Strategies opened 33 new positions and closed 27 in Q2 2024.
  • HighVista Strategies's portfolio value fell 2.4% quarter-over-quarter to $274M.

Based on HighVista Strategies's 13F filing for Q2 2024, filed 14 Aug 2024.